We are dedicated to the discovery and development of targeted therapeutics for cancer. Formed in 2009, we specialize in the discovery and early development of novel biopharmaceutical compounds. We build our pipeline through both internal research and through collaboration with other discovery partners. Our focus is a new generation of cancer drugs that target specific cellular processes not currently being exploited as cancer therapies. Our business model is to identify and evaluate preclinical anti-cancer targets with the objective of developing small molecule inhibitors through the pre-clinical phase. This research will come primarily from our own lab but also through acquisition of orphan IP.